» Articles » PMID: 38004809

SARS-CoV-2 Papain-like Protease Negatively Regulates the NLRP3 Inflammasome Pathway and Pyroptosis by Reducing the Oligomerization and Ubiquitination of ASC

Overview
Journal Microorganisms
Specialty Microbiology
Date 2023 Nov 25
PMID 38004809
Authors
Affiliations
Soon will be listed here.
Abstract

The interaction of viruses with hosts is complex, especially so with the antiviral immune systems of hosts, and the underlying mechanisms remain perplexing. Infection with may result in cytokine syndrome in the later stages, reflecting the activation of the antiviral immune response. However, viruses also encode molecules to negatively regulate the antiviral immune systems of hosts to achieve immune evasion and benefit viral replication during the early stage of infection. It has been observed that the papain-like protease (PLP) encoded by coronavirus could negatively regulate the host's IFNβ innate immunity. In this study, we first found that eight inflammasome-related genes were downregulated in CD14+ monocytes from COVID-19 patients. Subsequently, we observed that PLP negatively regulated the NLRP3 inflammasome pathway, inhibited the secretion of IL-1β, and decreased the caspase-1-mediated pyroptosis of human monocytes. The mechanisms for this may arise because PLP coimmunoprecipitates with ASC, reduces ASC ubiquitination, and inhibits ASC oligomerization and the formation of ASC specks. These findings suggest that PLP may inhibit strong immune defenses and provide the maximum advantage for viral replication. This research may allow us to better understand the flex function of CoV-encoding proteases and provide a new perspective on the innate immune responses against and other viruses.

Citing Articles

Activation and evasion of inflammasomes during viral and microbial infection.

Ren D, Ye X, Chen R, Jia X, He X, Tao J Cell Mol Life Sci. 2025; 82(1):56.

PMID: 39833559 PMC: 11753444. DOI: 10.1007/s00018-025-05575-2.


Saponin components in as potential candidate drugs for treating dementia.

Li S, Hou Z, Ye T, Song X, Hu X, Chen J Front Pharmacol. 2024; 15:1431894.

PMID: 39050746 PMC: 11266144. DOI: 10.3389/fphar.2024.1431894.

References
1.
Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H . Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020; 130(5):2620-2629. PMC: 7190990. DOI: 10.1172/JCI137244. View

2.
Hu H, Sun S . Ubiquitin signaling in immune responses. Cell Res. 2016; 26(4):457-83. PMC: 4822134. DOI: 10.1038/cr.2016.40. View

3.
Shi J, Zhou J, Zhang X, Hu W, Zhao J, Wang S . Single-Cell Transcriptomic Profiling of MAIT Cells in Patients With COVID-19. Front Immunol. 2021; 12:700152. PMC: 8363247. DOI: 10.3389/fimmu.2021.700152. View

4.
Harcourt B, Jukneliene D, Kanjanahaluethai A, Bechill J, Severson K, Smith C . Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity. J Virol. 2004; 78(24):13600-12. PMC: 533933. DOI: 10.1128/JVI.78.24.13600-13612.2004. View

5.
Gao X, Qin B, Chen P, Zhu K, Hou P, Wojdyla J . Crystal structure of SARS-CoV-2 papain-like protease. Acta Pharm Sin B. 2020; 11(1):237-245. PMC: 7467110. DOI: 10.1016/j.apsb.2020.08.014. View